Registered title, quoted from ClinicalTrials.gov
Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 5
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page
- Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
- Study siteFourth Affiliated Hospital of Guangxi Medical University广西医科大学第四附属医院LiuzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteWuzhou Red Cross Hospital梧州市红十字会医院WuzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07072000, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Newly diagnosed, histologically confirmed non-keratinizing carcinoma (WHO classification).
Inclusion criterion 1
Stage I-III disease (AJCC 9th edition).
Inclusion criterion 2
ECOG performance status 0-1 .
Inclusion criterion 8
Normal hepatic/renal function: total bilirubin ≤1.5×ULN, AST/ALT ≤2.5×ULN, alkaline phosphatase ≤2.5×ULN, creatinine clearance ≥60 mL/min.
Inclusion criterion 10
Male or non-pregnant female.
Inclusion criterion 6
Pregnancy/lactation (premenopausal women require pregnancy test; effective contraception mandated).
Exclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07072000, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Newly diagnosed, histologically confirmed non-keratinizing carcinoma (WHO classification).
- Stage I-III disease (AJCC 9th edition).
- Tumor extends to nasal cavity (including nasal septum).
- No distant metastasis (M0).
- Age 18-70 years.
- Male or non-pregnant female.
- Scheduled for radiotherapy.
- ECOG performance status 0-1 .
- Adequate bone marrow function: white blood cells >4×10⁹/L, hemoglobin >90 g/L, platelets >100×10⁹/L.
- Normal hepatic/renal function: total bilirubin ≤1.5×ULN, AST/ALT ≤2.5×ULN, alkaline phosphatase ≤2.5×ULN, creatinine clearance ≥60 mL/min.
- Written informed consent obtained.
Exclusion Criteria:
- Keratinizing squamous cell carcinoma (WHO Type I) or basaloid squamous cell carcinoma.
- Age <18 or >70 years.
- Recurrent disease or distant metastasis.
- No tumor extension into the nasal cavity (including the nasal septum).
- Prior malignancy (except adequately treated basal/squamous cell skin cancer or cervical carcinoma in situ).
- Pregnancy/lactation (premenopausal women require pregnancy test; effective contraception mandated).
- Prior radiotherapy (except non-melanoma skin cancer with lesions outside current portals).
- Preoperative chemotherapy or surgical resection of primary/neck lesions (excluding diagnostic procedures).
- Severe coexisting illness.
Quoted from ClinicalTrials.gov, NCT07072000, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07072000, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.